AbbVie

1158 articles with AbbVie

• AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis

  10/29/2020

  New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis[1]

• AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020

  10/28/2020

  AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9.

• AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis

  10/19/2020

  AbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ™ (upadacitinib) for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.

• AbbVie Announces Commencement of Registered Exchange Offers

  10/19/2020

   ("AbbVie") announced today the commencement of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019 (the " 2019 USD Notes"), (ii) $13,251,781,000 aggregate principal amount

• VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)

  10/16/2020

  AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older,

• AbbVie to Host Third-Quarter 2020 Earnings Conference Call

  10/6/2020

  AbbVie (NYSE: ABBV) will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens.

• 

  Top 12 Biotech Companies Hiring Now

  10/6/2020

  According to BioSpace research, 69% of biotech professionals feel they are on the verge of job burnout. Do you fall into that 69%? Is it time for a new job? Check out the top companies who are looking for candidates like you right now!

• AbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International Symposium

  10/2/2020

  - New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation - Presentation of real-world evidence assessing safety, tolerability, and potential benefits of treatment with BOTOX® (onabotulinumtoxinA) in combination with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for chronic migraine prevention - Oral presentation of Phase 3 data measuring the efficacy and sa

• SkinMedica® Launches TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™

  9/30/2020

  Allergan Aesthetics, an AbbVie company, announced the launch of SkinMedica® TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™ treatments.

• AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury

  9/28/2020

  - Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury - Orphan Drug Designation is given to a drug or biologic for the treatment, diagnosis or prevention of a rare disease or condition¹ - Fast Track Designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs²

• Voting for the 2020 AbbVie CF Scholarship Thriving Student Awards is Open to the Public Until September 30

  9/16/2020

  - Forty students received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement/extracurricular activities - The public is now invited to cast their votes to help determine this year's Thriving Scholars - Scholarships totaling $25,000 each - the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship - will be awarded to two deserving students  

• AbbVie Declares Quarterly Dividend - Sep 11, 2020

  9/11/2020

  The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.18 per share.

• AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®

  9/11/2020

  AbbVie (NYSE: ABBV) today announced it will present results from several studies, including the DYSCOVER study evaluating the efficacy of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease (PD), at the 2020 International Congress of Parkinson's Disease and Movement Disorders® Virtual Congress, September 12-16

• 

  Biopharma Update on the Novel Coronavirus: September 11

  9/11/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.

• AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

  9/4/2020

  AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)

• 

  The Sky Remains the Limit for AbbVie with New Collaborative Partnerships

  9/4/2020

  AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.

• AbbVie to Present at the Morgan Stanley Healthcare Conference - Sep 03, 2020

  9/3/2020

  AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020.

• 

  House Committee Subpoenas AbbVie Over Drug Pricing for Humira, Imbruvica

  9/2/2020

  Shares of AbbVie fell nearly 4% Tuesday following the issuance of a subpoena from the U.S. House Oversight and Reform Committee regarding an ongoing investigation into drug pricing.

• 'Say No to Chronic Migraine Monday' Urges People Living with Chronic Migraine to Seek Help from a Headache Specialist

  8/31/2020

  Each Monday throughout Pain Awareness Month, online influencers share motivations for finding a headache specialist to discuss treatment options

• AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis

  8/25/2020

  - RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis[1] - In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p<0.001)[1] - A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year - This submission represents AbbVie's ongoing comm